MapLight Therapeutics, Inc. (MPLT)
Nasdaq: MPLT · Pharmaceutical Preparations · Redwood City, CA · filing with the SEC since 2019
Who owns MapLight Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Catalyst4, Inc. holds 49.9% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed Aug 18, 2026 says.
Directors and officers
15
report now, of 15 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Catalyst4, Inc.
SCHEDULE 13D/A · filed Aug 18, 2026 · Common Stock, $0.0001 par value per share · 47.9% in Aug 3, 2026
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed May 15, 2026 · COMMON STOCK · 6.2% in Feb 17, 2026
Forbion Growth Opportunities Fund III Cooperatief U.A.
SCHEDULE 13G · filed Feb 17, 2026 · Voting Common Stock, par value $0.0001 per share
Nan Fung Group Holdings Limited
SCHEDULE 13G · filed Aug 20, 2026 · Common Stock, par value $0.0001 per share
Novo Holdings A/S
SCHEDULE 13D/A · filed Jul 31, 2026 · Voting Common Stock, par value $0.0001 per share · reported falling below 5%, from 8.4% in Nov 4, 2025
What MPLT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Advisor Agreement
An investee · investee · invested in, named in the 10-K filed Mar 26, 2026
Insider tradesForm 4
145sales
5purchases
88sales on a scheduled plan
8people selling
$30.2Msold, in dollars
$800,000bought, in dollars
Open-market trades on Form 4 from Oct 16, 2025 to Oct 16, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 16, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window13 of 17 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kroeger Christopher A. | Chief Executive Officer | 30 | $13.1M | 19 | 0 | $0 |
| Gillis Jonathan | CAO and Interim CFO | 14 | $3.6M | 12 | 0 | $0 |
| Foff Erin Pennock | Chief Medical Officer | 23 | $3.5M | 19 | 0 | $0 |
| Kreitzer Anatol | Chief Discovery Officer | 12 | $2.9M | 10 | 0 | $0 |
| Lillie James Woodruff | Chief Scientific Officer | 21 | $2.7M | 10 | 0 | $0 |
| Hanson Kristopher | General Counsel | 20 | $1.7M | 9 | 0 | $0 |
| Malenka Robert C. | director | 14 | $1.6M | 1 | 0 | $0 |
| Setia Vishwas | Chief Financial Officer | 11 | $1.1M | 8 | 0 | $0 |
| Catalyst4, Inc. | 10% owner | 0 | $0 | 0 | 6 | $158M |
| Pavlov George | Chief Medical Officer | 0 | $0 | 0 | 3 | $400,000 |
| Cox Troy | director | 0 | $0 | 0 | 1 | $100,000 |
| Garnett Timothy John | director | 0 | $0 | 0 | 1 | $300,000 |
| Novo Holdings A/s | 10% owner | 0 | $0 | 0 | 1 | $16.2M |